December 2024

BALDWIN PARK, Calif., Dec. 19, 2024 /PRNewswire/ — StemCyte announced a significant breakthrough in its Phase IIa clinical trial of HPC, Cord Blood (HPC, CB) for treating Post-COVID Syndrome (Long COVID). This trial results demonstrated that cord blood significantly improved fatigue symptom

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: